基于遗传风险分层以减少血友病A早期治疗中抑制物发生:SIPPET分析
该分析基于SIPPET随机试验,比较重组凝血因子VIII(rFVIII)与血浆源性凝血因子VIII(pdFVIII)在初治重型血友病A患者中抑制物发生的差异,并按F8突变风险分层。结果显示,低遗传风险患者接受rFVIII时抑制物风险显著高于pdFVIII,遗传风险分层未能识别可安全使用rFVIII的患者。
要点
- 低遗传风险患者接受rFVIII的抑制物累积发生率为43%,而pdFVIII为0%。
- 高遗传风险患者接受pdFVIII的抑制物累积发生率为31%,rFVIII为47%。
- 遗传风险分层未能识别可安全使用rFVIII的患者,低风险患者接受rFVIII时受害更大。
核心结论
- 按F8突变进行的风险分层不能识别出在免疫原性方面可安全接受rFVIII治疗的患者。
- 低遗传风险患者接受rFVIII治疗时遭受不成比例的伤害(风险增量43%),需伤害人数为2.3。
研究设计与样本
- 该研究为基于SIPPET随机试验的分析,共纳入235例既往未接受过FVIII浓缩物治疗的重型血友病A患者。
- 其中197例携带无效突变被归为高风险,38例携带非无效突变被归为低风险。
主要发现
- 接受pdFVIII治疗时,低遗传风险患者未发生抑制物,而高风险患者的累积发生率为31%。
- 接受rFVIII治疗时,低风险和高风险患者的抑制物累积发生率分别为43%和47%,差异不大。
- rFVIII的需伤害人数在高遗传风险患者中为6.3,在低风险患者中仅为2.3。
关键数值与推荐
- 低遗传风险患者接受rFVIII的抑制物累积发生率为43%,接受pdFVIII为0%。
- 高遗传风险患者接受pdFVIII的抑制物累积发生率为31%,接受rFVIII为47%。
- rFVIII的需伤害人数在高遗传风险患者中为6.3,低风险患者中为2.3。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A recent randomized trial, the Survey of Inhibitors in Plasma-Product Exposed Toddlers (SIPPET), showed a higher risk of inhibitor development with recombinant factor VIII (rFVIII) than plasma-derived concentrates (pdFVIII). We investigated whether risk stratification by F8 mutation identifies patients who do not suffer this deleterious effect of rFVIII. Among 235 randomized patients with severe hemophilia A previously untreated with FVIII concentrate, 197 with null mutations were classified as high risk and 38 with non-null mutations were classified as low risk. With pdFVIII, no inhibitors occurred in those with low genetic risk, whereas high-risk patients had a cumulative incidence of 31%. The risk among low- and high-risk patients did not differ much when they were treated with rFVIII (43% and 47%, respectively). This implies that patients with low genetic risk suffer disproportionate harm when treated with rFVIII (risk increment 43%), as also shown by the number needed to harm with rFVIII, which was 6.3 for genetically high-risk patients and only 2.3 for low-risk patients. Risk stratification by F8 mutation does not identify patients who can be safely treated with rFVIII, as relates to immunogenicity. This trial was registered at the European Clinical Trials Database (EudraCT) as #2009-011186-88 and at www.clinicaltrials.gov as #NCT01064284.
引用
- Rosendaal FR, Palla R, Garagiola I, et al. Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis. Blood. 2017. PMID: 28768627. doi:10.1182/blood-2017-06-791756
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。